Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review (Q34957303)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2 references

9 October 2019

22 November 2020

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

chronic obstructive pulmonary disease

2 references

9 October 2019

22 November 2020

respiratory system

1 reference

9 October 2019

1 reference

based on heuristic

inferred from title

forced expiratory volume

1 reference

22 November 2020

systematic review

1 reference

based on heuristic

inferred from title

6

object named as

Gill Worthy

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Marie Westwood

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jean Bourbeau

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Paul W Jones

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Annamaria Cerulli

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gorana Capkun-Niggli

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

8 April 2011

3 references

Europe PubMed Central

PubMed publication ID

5 August 2017

9 October 2019

22 November 2020

Respiratory Research

3 references

Europe PubMed Central

PubMed publication ID

5 August 2017

9 October 2019

22 November 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

2 references

Europe PubMed Central

9 October 2019

Europe PubMed Central

22 November 2020

copyright status

0 references

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

What have we learned from large drug treatment trials in COPD?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Minimal clinically important differences in COPD lung function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

The MCID of the transition dyspnea index is a total score of one unit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

The effect of tiotropium on exacerbations and airflow in patients with COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

The strengths and limitations of meta-analyses based on aggregate data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Health status measurement in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Measuring health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

8 July 2018

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-40

21 January 2018

The UPLIFT study (Understanding Potential Long-term Impacts on Function with Tiotropium)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

26 October 2018

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090353

26 October 2018

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

St. George's Respiratory Questionnaire: MCID

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

1 reference

https://pubmed.ncbi.nlm.nih.gov/21477298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1465-9921-12-40

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34957303&oldid=2197091675"